Fujifilm Diosynth Biotechnologies USA, a biologics contract development and manufacturing organization, with experience focused on the development and manufacture of recombinant biopharmaceuticals including proteins, vaccines, and monoclonal antibodies, completed the construction of a new three-story, 62,000 square-foot state-of-the-art facility in Research Triangle Park, NC.

“The construction and completion of this building reflects the continued commitment of our organization to provide our clients with the infrastructure to efficiently and innovatively bring their products to the clinic and beyond for the benefit of their patients,” said Steve Bagshaw, chief executive officer, Fujifilm Diosynth Biotechnologies.

The new building, called BioProcess Innovation Center, houses the company’s process and analytical research and development, process sciences and stability groups. These will concentrate on providing services for process invention, design and development and process and product characterization.

“The design of the facility reflects our core philosophy of cross-functional collaboration to research and process development, which is a key differentiator of our company,” said Martin Meeson, president, Fujifilm Diosynth Biotechnologies USA.